BrainsWay (BWAY)

[midastouch017]

BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom

https://finance.yahoo.com/news/brainsway-reports-open-market-stock-141500758.html

BURLINGTON, Mass. and JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported a recent open market purchase of BrainsWay American Depositary Receipts (ADRs) by Yossi Ben Shalom, an independent Director on the Company’s Board.

Mr. Ben Shalom purchased 147,500 ADRs (representing 295,000 ordinary shares) on the open market for a total amount of $277,300, at an average price of $1.88 per ADR.

“This investment reflects my strong belief in the value of BrainsWay, its technology, and its strategic vision,” stated Mr. Ben Shalom. “The Company’s impressive dossier of clinical evidence has shown that its unique, patented, and FDA-cleared Deep TMS™ platform is highly impactful in treating multiple indications. Based on its effective business model and industry leading R&D capabilities, as well as favorable market trends, I believe BrainsWay represents a highly compelling long-term strategic investment.”

The ADR purchase was made on the Nasdaq exchange, and follows recent open market stock purchases by additional BrainsWay board members, including its Chairman, Dr. David Zacut, and Avner Hagai. The Company’s ordinary shares are listed and traded on the Tel Aviv Stock Exchange.

In addition to having served on BrainsWay’s board since 2018, Mr. Ben Shalom is a board member at several other companies, and is a co-founder of D.B.S.I, a private investment company specializing in mature companies that are positioned globally for high growth.